ID

37762

Description

Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00912444

Lien

https://clinicaltrials.gov/show/NCT00912444

Mots-clés

Versions (1)
  1. 22/08/2019 22/08/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

22 août 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT00912444

Anglais

Eligibility Breast Cancer NCT00912444

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
women aged ≥ 18 years and < 70 years
Description

Gender | Age

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
karnofsky performance status (kps) ≥ 70
Description

Karnofsky Performance Status

Type de données

boolean

Alias
UMLS CUI [1]
C0206065
at least one measurable disease according to the recist. histologically confirmed invasive breast cancer (excluding inflammatory breast cancer), t2n1 or locally advanced breast cancer (t3-4n0-3 or t0-4n2-3)
Description

Measurable Disease Quantity | Invasive carcinoma of breast | Exception Inflammatory Breast Carcinoma | Breast Carcinoma TNM Breast tumor staging | Locally advanced breast cancer TNM Breast tumor staging

Type de données

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
UMLS CUI [2]
C0853879
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0278601
UMLS CUI [4,1]
C0678222
UMLS CUI [4,2]
C0474926
UMLS CUI [5,1]
C3495949
UMLS CUI [5,2]
C0474926
biopsy specimens are available for er, pgr and her2 detection, patients should be with triple negative or her2 positive breast cancer, her2 positivity is defined as fish/cish her2 positive or ihc her2 3+, triple-negative disease defined as negativity for er, pgr and her2
Description

Biopsy sample Estrogen Receptor Detection | Biopsy sample Progesterone Receptor Detection | Biopsy sample HER2 Detection | Triple Negative Breast Neoplasms | HER2-positive carcinoma of breast | HER2 Positive FISH | HER2 Positive CISH | HER2 Positive Immunohistochemistry

Type de données

boolean

Alias
UMLS CUI [1,1]
C0677862
UMLS CUI [1,2]
C0034804
UMLS CUI [1,3]
C1511790
UMLS CUI [2,1]
C0677862
UMLS CUI [2,2]
C0034833
UMLS CUI [2,3]
C1511790
UMLS CUI [3,1]
C0677862
UMLS CUI [3,2]
C0242957
UMLS CUI [3,3]
C1511790
UMLS CUI [4]
C3539878
UMLS CUI [5]
C1960398
UMLS CUI [6,1]
C2348909
UMLS CUI [6,2]
C0162789
UMLS CUI [7,1]
C2348909
UMLS CUI [7,2]
C1516514
UMLS CUI [8,1]
C2348909
UMLS CUI [8,2]
C0021044
adequate bone marrow function: neutrophil ≥ 1.5*109/l; hb ≥ 100g/l; plt ≥ 100*109/l
Description

Bone Marrow function | Neutrophil count | Hemoglobin measurement | Platelet Count measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0200633
UMLS CUI [3]
C0518015
UMLS CUI [4]
C0032181
an estimated life expectancy of at least 12 months
Description

Life Expectancy

Type de données

boolean

Alias
UMLS CUI [1]
C0023671
willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up
Description

Biopsy | Neoadjuvant Chemotherapy | Patients Available Treatment | Patients Available Follow-up

Type de données

boolean

Alias
UMLS CUI [1]
C0005558
UMLS CUI [2,1]
C0600558
UMLS CUI [2,2]
C3665472
UMLS CUI [3,1]
C0030705
UMLS CUI [3,2]
C0470187
UMLS CUI [3,3]
C0087111
UMLS CUI [4,1]
C0030705
UMLS CUI [4,2]
C0470187
UMLS CUI [4,3]
C3274571
women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study
Description

Childbearing Potential Urine pregnancy test negative | Childbearing Potential Serum pregnancy test negative | Childbearing Potential Contraceptive methods

Type de données

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430057
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0430061
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
written informed consent according to the gcp
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior systemic or loco-regional treatment of breast cancer, including chemotherapy
Description

Systemic therapy Breast Carcinoma | Therapy Local-Regional Breast Carcinoma | Chemotherapy Breast Carcinoma

Type de données

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0678222
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1947913
UMLS CUI [2,3]
C0678222
UMLS CUI [3,1]
C0392920
UMLS CUI [3,2]
C0678222
metastatic breast cancer
Description

Secondary malignant neoplasm of female breast

Type de données

boolean

Alias
UMLS CUI [1]
C0346993
with a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma
Description

Malignant Neoplasms | Exception Carcinoma in situ of uterine cervix | Exception Basal cell carcinoma

Type de données

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0851140
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007117
patients with medical conditions that indicate intolerant to neoadjuvant therapy and related treatment, including uncontrolled pulmonary disease, diabetes mellitis, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease
Description

Medical condition intolerant Neoadjuvant Therapy | Medical condition intolerant Therapeutic procedure Similar | Lung disease Uncontrolled | Diabetes Mellitus | Communicable Disease Severe | Peptic Ulcer | Blood Coagulation Disorder | Connective Tissue Disease | Myelosuppression adult

Type de données

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0231200
UMLS CUI [1,3]
C0600558
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0231200
UMLS CUI [2,3]
C0087111
UMLS CUI [2,4]
C2348205
UMLS CUI [3,1]
C0024115
UMLS CUI [3,2]
C0205318
UMLS CUI [4]
C0011849
UMLS CUI [5,1]
C0009450
UMLS CUI [5,2]
C0205082
UMLS CUI [6]
C0030920
UMLS CUI [7]
C0005779
UMLS CUI [8]
C0009782
UMLS CUI [9]
C0549484
inadequate liver function (bilirubin > 1.0 times upper normal limit [unl] and alt and/or ast> 1.5 unl associated with alkaline phosphatase > 2.5 unl; inadequate renal function (creatinine > 1.0 times unl and in case of limit value, creatinine clearance < 60 ml/min)
Description

Liver function Inadequate | Elevated total bilirubin | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised | Renal function Inadequate | Serum creatinine raised | Creatinine clearance measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0205412
UMLS CUI [2]
C0741494
UMLS CUI [3]
C0151905
UMLS CUI [4]
C0151904
UMLS CUI [5]
C0151849
UMLS CUI [6,1]
C0232804
UMLS CUI [6,2]
C0205412
UMLS CUI [7]
C0700225
UMLS CUI [8]
C0373595
contraindication for using dexamethasone
Description

Medical contraindication Dexamethasone

Type de données

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0011777
history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (systolic bp > 180 mmhg or diastolic bp > 100 mmhg)
Description

Congestive heart failure | Angina Pectoris Uncontrolled | Angina Pectoris Symptomatic | Cardiac Arrhythmia | Myocardial Infarction | Poor hypertension control | Systolic Pressure | Diastolic blood pressure

Type de données

boolean

Alias
UMLS CUI [1]
C0018802
UMLS CUI [2,1]
C0002962
UMLS CUI [2,2]
C0205318
UMLS CUI [3,1]
C0002962
UMLS CUI [3,2]
C0231220
UMLS CUI [4]
C0003811
UMLS CUI [5]
C0027051
UMLS CUI [6]
C0421190
UMLS CUI [7]
C0871470
UMLS CUI [8]
C0428883
has peripheral neuropathy ≥ grade 1
Description

Peripheral Neuropathy CTCAE Grades

Type de données

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
patient is pregnant or breast feeding
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
known severe hypersensitivity to any drugs in this study
Description

Severe allergy Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1,1]
C2945656
UMLS CUI [1,2]
C0013230
treatment with any investigational drugs within 30 days before the beginning of study treatment
Description

Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
Retour au début de la page

Similar models

Eligibility Breast Cancer NCT00912444

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Age
Item
women aged ≥ 18 years and < 70 years
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Karnofsky Performance Status
Item
karnofsky performance status (kps) ≥ 70
boolean
C0206065 (UMLS CUI [1])
Measurable Disease Quantity | Invasive carcinoma of breast | Exception Inflammatory Breast Carcinoma | Breast Carcinoma TNM Breast tumor staging | Locally advanced breast cancer TNM Breast tumor staging
Item
at least one measurable disease according to the recist. histologically confirmed invasive breast cancer (excluding inflammatory breast cancer), t2n1 or locally advanced breast cancer (t3-4n0-3 or t0-4n2-3)
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0853879 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0278601 (UMLS CUI [3,2])
C0678222 (UMLS CUI [4,1])
C0474926 (UMLS CUI [4,2])
C3495949 (UMLS CUI [5,1])
C0474926 (UMLS CUI [5,2])
Biopsy sample Estrogen Receptor Detection | Biopsy sample Progesterone Receptor Detection | Biopsy sample HER2 Detection | Triple Negative Breast Neoplasms | HER2-positive carcinoma of breast | HER2 Positive FISH | HER2 Positive CISH | HER2 Positive Immunohistochemistry
Item
biopsy specimens are available for er, pgr and her2 detection, patients should be with triple negative or her2 positive breast cancer, her2 positivity is defined as fish/cish her2 positive or ihc her2 3+, triple-negative disease defined as negativity for er, pgr and her2
boolean
C0677862 (UMLS CUI [1,1])
C0034804 (UMLS CUI [1,2])
C1511790 (UMLS CUI [1,3])
C0677862 (UMLS CUI [2,1])
C0034833 (UMLS CUI [2,2])
C1511790 (UMLS CUI [2,3])
C0677862 (UMLS CUI [3,1])
C0242957 (UMLS CUI [3,2])
C1511790 (UMLS CUI [3,3])
C3539878 (UMLS CUI [4])
C1960398 (UMLS CUI [5])
C2348909 (UMLS CUI [6,1])
C0162789 (UMLS CUI [6,2])
C2348909 (UMLS CUI [7,1])
C1516514 (UMLS CUI [7,2])
C2348909 (UMLS CUI [8,1])
C0021044 (UMLS CUI [8,2])
Bone Marrow function | Neutrophil count | Hemoglobin measurement | Platelet Count measurement
Item
adequate bone marrow function: neutrophil ≥ 1.5*109/l; hb ≥ 100g/l; plt ≥ 100*109/l
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0200633 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
Life Expectancy
Item
an estimated life expectancy of at least 12 months
boolean
C0023671 (UMLS CUI [1])
Biopsy | Neoadjuvant Chemotherapy | Patients Available Treatment | Patients Available Follow-up
Item
willing to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up
boolean
C0005558 (UMLS CUI [1])
C0600558 (UMLS CUI [2,1])
C3665472 (UMLS CUI [2,2])
C0030705 (UMLS CUI [3,1])
C0470187 (UMLS CUI [3,2])
C0087111 (UMLS CUI [3,3])
C0030705 (UMLS CUI [4,1])
C0470187 (UMLS CUI [4,2])
C3274571 (UMLS CUI [4,3])
Childbearing Potential Urine pregnancy test negative | Childbearing Potential Serum pregnancy test negative | Childbearing Potential Contraceptive methods
Item
women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study
boolean
C3831118 (UMLS CUI [1,1])
C0430057 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430061 (UMLS CUI [2,2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Informed Consent
Item
written informed consent according to the gcp
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Systemic therapy Breast Carcinoma | Therapy Local-Regional Breast Carcinoma | Chemotherapy Breast Carcinoma
Item
prior systemic or loco-regional treatment of breast cancer, including chemotherapy
boolean
C1515119 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C1947913 (UMLS CUI [2,2])
C0678222 (UMLS CUI [2,3])
C0392920 (UMLS CUI [3,1])
C0678222 (UMLS CUI [3,2])
Secondary malignant neoplasm of female breast
Item
metastatic breast cancer
boolean
C0346993 (UMLS CUI [1])
Malignant Neoplasms | Exception Carcinoma in situ of uterine cervix | Exception Basal cell carcinoma
Item
with a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0851140 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
Medical condition intolerant Neoadjuvant Therapy | Medical condition intolerant Therapeutic procedure Similar | Lung disease Uncontrolled | Diabetes Mellitus | Communicable Disease Severe | Peptic Ulcer | Blood Coagulation Disorder | Connective Tissue Disease | Myelosuppression adult
Item
patients with medical conditions that indicate intolerant to neoadjuvant therapy and related treatment, including uncontrolled pulmonary disease, diabetes mellitis, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease
boolean
C3843040 (UMLS CUI [1,1])
C0231200 (UMLS CUI [1,2])
C0600558 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0231200 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C2348205 (UMLS CUI [2,4])
C0024115 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0011849 (UMLS CUI [4])
C0009450 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C0030920 (UMLS CUI [6])
C0005779 (UMLS CUI [7])
C0009782 (UMLS CUI [8])
C0549484 (UMLS CUI [9])
Liver function Inadequate | Elevated total bilirubin | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised | Renal function Inadequate | Serum creatinine raised | Creatinine clearance measurement
Item
inadequate liver function (bilirubin > 1.0 times upper normal limit [unl] and alt and/or ast> 1.5 unl associated with alkaline phosphatase > 2.5 unl; inadequate renal function (creatinine > 1.0 times unl and in case of limit value, creatinine clearance < 60 ml/min)
boolean
C0232741 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
C0741494 (UMLS CUI [2])
C0151905 (UMLS CUI [3])
C0151904 (UMLS CUI [4])
C0151849 (UMLS CUI [5])
C0232804 (UMLS CUI [6,1])
C0205412 (UMLS CUI [6,2])
C0700225 (UMLS CUI [7])
C0373595 (UMLS CUI [8])
Medical contraindication Dexamethasone
Item
contraindication for using dexamethasone
boolean
C1301624 (UMLS CUI [1,1])
C0011777 (UMLS CUI [1,2])
Congestive heart failure | Angina Pectoris Uncontrolled | Angina Pectoris Symptomatic | Cardiac Arrhythmia | Myocardial Infarction | Poor hypertension control | Systolic Pressure | Diastolic blood pressure
Item
history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension (systolic bp > 180 mmhg or diastolic bp > 100 mmhg)
boolean
C0018802 (UMLS CUI [1])
C0002962 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0002962 (UMLS CUI [3,1])
C0231220 (UMLS CUI [3,2])
C0003811 (UMLS CUI [4])
C0027051 (UMLS CUI [5])
C0421190 (UMLS CUI [6])
C0871470 (UMLS CUI [7])
C0428883 (UMLS CUI [8])
Peripheral Neuropathy CTCAE Grades
Item
has peripheral neuropathy ≥ grade 1
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
patient is pregnant or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Severe allergy Investigational New Drugs
Item
known severe hypersensitivity to any drugs in this study
boolean
C2945656 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Investigational New Drugs
Item
treatment with any investigational drugs within 30 days before the beginning of study treatment
boolean
C0013230 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial